CA 125 Half-Life in Ovarian Cancer
Author Information
Author(s): C.A. Yedema, P. Kenemans, F. Voorhorst, G. Bon, C. Schijf, L. Beex, A. Verstraeten, J. Hilgers, J. Vermorken
Primary Institution: Free University Hospital, Amsterdam, The Netherlands; University Hospital, Nijmegen, The Netherlands
Hypothesis
The study aims to evaluate the role of CA 125 regression early in the course of therapy and to test models for calculating the CA 125 half-life.
Conclusion
Patients with a CA 125 normalisation after three courses of chemotherapy and those with a CA 125 half-life less than 20 days had significantly better survival rates.
Supporting Evidence
- Patients with a CA 125 normalisation after three courses had a median survival of 27 months compared to 14 months for those without.
- CA 125 half-lives less than 20 days were associated with better survival outcomes.
- Stage of disease was the most predictive variable for survival.
Takeaway
This study looked at a blood test called CA 125 in women with ovarian cancer to see how it changes after treatment, and found that faster changes can mean better chances of survival.
Methodology
A retrospective study using CA 125 measurements from patients between cytoreductive surgery and completion of three courses of chemotherapy.
Limitations
The study only included patients with available pre-surgery CA 125 levels and excluded those with certain previous medical histories.
Participant Demographics
Median age of participants was 61 years, with a range of 32-81 years; included patients were classified into stages I-IV of ovarian cancer.
Statistical Information
P-Value
P = 0.003
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website